Lipocine Company Profile (NASDAQ:LPCN)

About Lipocine

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: LPCN
  • CUSIP:
Key Metrics:
  • Previous Close: $4.41
  • 50 Day Moving Average: $3.73
  • 200 Day Moving Average: $6.80
  • 52-Week Range: $2.51 - $14.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.02
  • P/E Growth: 0.00
  • Market Cap: $80.52M
  • Outstanding Shares: 18,258,000
  • Beta: 1.75
Profitability:
  • Return on Equity: -61.45%
  • Return on Assets: -57.32%
Debt:
  • Current Ratio: 12.86%
  • Quick Ratio: 12.86%
Additional Links:
Companies Related to Lipocine:

Analyst Ratings

Consensus Ratings for Lipocine (NASDAQ:LPCN) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (36.05% upside)

Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
Show:
DateFirmActionRatingPrice TargetDetails
8/10/2016Canaccord GenuityReiterated RatingBuy$6.00View Rating Details
7/22/2015Roth CapitalInitiated CoverageBuy$36.00View Rating Details
7/17/2015Evercore ISIInitiated CoverageBuy$18.00View Rating Details
7/16/2015Evercore Partners Inc.Initiated CoverageBuy$18.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Lipocine (NASDAQ:LPCN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/9/2016Q2($0.37)($0.32)ViewN/AView Earnings Details
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details
8/11/2015($0.20)($0.26)ViewN/AView Earnings Details
5/7/2015($0.35)($0.23)ViewN/AView Earnings Details
3/11/2015($0.35)($0.32)ViewN/AView Earnings Details
11/10/2014($0.58)($0.32)ViewN/AView Earnings Details
8/13/2014($0.42)($0.55)ViewN/AView Earnings Details
5/14/2014($0.35)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lipocine (NASDAQ:LPCN)
Current Year EPS Consensus Estimate: $-1.31 EPS
Next Year EPS Consensus Estimate: $-1.46 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.34)($0.19)($0.27)
Q2 20162($0.38)($0.34)($0.36)
Q3 20162($0.32)($0.29)($0.31)
Q4 20162($0.46)($0.28)($0.37)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Lipocine (NASDAQ:LPCN)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 47.23%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00View SEC Filing  
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00View SEC Filing  
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Lipocine (NASDAQ:LPCN)
DateHeadline
biz.yahoo.com logoLIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:LPCN)
biz.yahoo.com - September 28 at 5:45 PM
News IconUpgrades And Downgrades For Lipocine Inc (LPCN) - NewsDen (NASDAQ:LPCN)
newsden.net - September 28 at 10:53 AM
News IconLipocine Rallies Premarket as Phase 2b LPCN 1111 Meets Top-Line Results (NASDAQ:LPCN) - Post News (NASDAQ:LPCN)
www.kentuckypostnews.com - September 28 at 10:53 AM
News IconNoteworthy Analyst Ratings of Two Stocks Lipocine Inc (NASDAQ ... - The Voice Registrar (NASDAQ:LPCN)
voiceregistrar.com - September 28 at 10:53 AM
benzinga.com logoMid-Day Market Update: Crude Oil Up 3.3%; Chemtura Shares Surge Following Acquisition News (NASDAQ:LPCN)
www.benzinga.com - September 26 at 6:00 PM
baystreet.ca logoLipocine's Shares Surge as Company's Oral Testosterone Replacement Therapy Successful in Mid-Stage Study (NASDAQ:LPCN)
www.baystreet.ca - September 26 at 6:00 PM
4-traders.com logoLipocine : LPCN) Announces Phase 2b Study Results for LPCN 1111 (NASDAQ:LPCN)
www.4-traders.com - September 26 at 6:00 PM
4-traders.com logoLIPOCINE INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:LPCN)
www.4-traders.com - September 26 at 10:38 AM
globenewswire.com logoLipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy (NASDAQ:LPCN)
globenewswire.com - September 26 at 10:38 AM
rttnews.com logoLipocine Inc. (LPCN) Has Climbed To A 3-Month High On Phase 2 Study Results (NASDAQ:LPCN)
www.rttnews.com - September 26 at 10:38 AM
globenewswire.com logoLipocine to Present at 2016 Ladenburg Thalmann Healthcare Conference - GlobeNewswire (press release) (NASDAQ:LPCN)
globenewswire.com - September 21 at 4:13 PM
News IconBrokerages Set $23.50 Target Price for Lipocine Inc (NASDAQ:LPCN) - DailyQuint (NASDAQ:LPCN)
dailyquint.com - September 21 at 4:13 PM
finance.yahoo.com logoLipocine to Present at 2016 Ladenburg Thalmann Healthcare Conference (NASDAQ:LPCN)
finance.yahoo.com - September 20 at 11:05 AM
News IconMarket Mover: Lipocine Inc. (NASDAQ:LPCN) , Aclaris Therapeutics, Inc. (NASDAQ:ACRS) , - Wall Street Times (press release) (NASDAQ:LPCN)
www.wallstreetnews24.com - September 16 at 10:54 AM
News IconPlacing Lipocine Inc. (NASDAQ:LPCN) Shares Under the Microscope - Post News (NASDAQ:LPCN)
www.kentuckypostnews.com - September 8 at 9:52 AM
News IconHC Stocks Analysis= Gilead Sciences, Inc. (GILD), Lipocine Inc (NASDAQ:LPCN) - share market updates (press release) (NASDAQ:LPCN)
sharemarketupdates.com - September 8 at 9:52 AM
News IconSearch Solution Group Receives SmartCEO Award in 2016 (NASDAQ:LPCN)
www.econotimes.com - August 30 at 9:17 AM
finance.yahoo.com logoDEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses in Excess of $25,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 30 at 9:17 AM
globenewswire.com logoDEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Lawsuit Involving ... - GlobeNewswire (press release) (NASDAQ:LPCN)
globenewswire.com - August 29 at 5:53 PM
finance.yahoo.com logoDEADLINE TOMORROW: The Law Offices of Vincent Wong Reminds Investors of a Class Action Lawsuit Involving Lipocine Inc. and a Lead Plaintiff Deadline of August 30, 2016 - LPCN (NASDAQ:LPCN)
finance.yahoo.com - August 29 at 5:53 PM
finance.yahoo.com logoFINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lipocine, Inc. (LPCN) & Lead Plaintiff Deadline August 30, 2016 (NASDAQ:LPCN)
finance.yahoo.com - August 26 at 5:47 PM
finance.yahoo.com logo4-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 26 at 5:47 PM
News IconStoneRiver Collaborates with Microsoft to Deliver Superior Value and Agility for Customers (NASDAQ:LPCN)
www.econotimes.com - August 25 at 11:02 AM
News IconSHAREHOLDER ALERT Levi Korsinsky, LLP Reminds Investors in Lipocine Inc. of a Class Action Lawsuit and a Lead ... - EconoTimes (NASDAQ:LPCN)
www.econotimes.com - August 24 at 5:50 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors in Lipocine Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 30, 2016 – LPCN (NASDAQ:LPCN)
finance.yahoo.com - August 24 at 5:50 PM
finance.yahoo.com logo6- DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 24 at 5:50 PM
finance.yahoo.com logoUPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 22 at 6:01 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Rosen Law Firm Reminds Lipocine Inc. Investors of Important August 30 Deadline in Class Action Filed by Firm - LPCN (NASDAQ:LPCN)
finance.yahoo.com - August 22 at 6:01 PM
finance.yahoo.com logoUPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 22 at 6:01 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lipocine, Inc. (LPCN) & Lead Plaintiff Deadline: August 30, 2016 (NASDAQ:LPCN)
finance.yahoo.com - August 22 at 10:36 AM
finance.yahoo.com logoFINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lipocine, Inc. (LPCN) & Lead Plaintiff Deadline: August 30, 2016 (NASDAQ:LPCN)
finance.yahoo.com - August 22 at 10:36 AM
News IconStock Tracking Lower for the Quarter: Lipocine Inc. (NASDAQ:LPCN) - Post News (NASDAQ:LPCN)
www.kentuckypostnews.com - August 21 at 10:14 AM
News IconINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors in Lipocine Inc. of a Class Action Lawsuit & a Lead Plaintiff Deadlin... (NASDAQ:LPCN)
ih.advfn.com - August 20 at 10:08 AM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 20 at 10:08 AM
globenewswire.com logoDEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Lipocine Inc. Of Upcoming Deadline - GlobeNewswire (press release) (NASDAQ:LPCN)
globenewswire.com - August 19 at 5:58 PM
News IconSeeing Active Stock of Yesterday- Lipocine Inc.'s (LPCN) - Hot Stocks Point (NASDAQ:LPCN)
www.hotstockspoint.com - August 19 at 5:58 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors in Lipocine Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 30, 2016 (NASDAQ:LPCN)
finance.yahoo.com - August 19 at 5:58 PM
finance.yahoo.com logoDEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Lipocine Inc. Of Upcoming Deadline (NASDAQ:LPCN)
finance.yahoo.com - August 18 at 6:01 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 18 at 6:01 PM
tmcnet.com logoGPM Reminds Investors of the August 30th Deadline in the Class Action Lawsuit Against Lipocine Inc. and Encourages Investors to Contact the Firm (NASDAQ:LPCN)
www.tmcnet.com - August 17 at 6:13 PM
News IconGPM Reminds Investors of the August 30th Deadline in the Class Action Lawsuit Against Lipocine Inc. & Encourages Investors to... (NASDAQ:LPCN)
ih.advfn.com - August 17 at 6:13 PM
finance.yahoo.com logoLIPOCINE INC. Financials (NASDAQ:LPCN)
finance.yahoo.com - August 17 at 6:13 PM
finance.yahoo.com logoAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 17 at 9:03 AM
4-traders.com logoISA Iowa Soybean Association : Seven farmers elected to the Iowa Soybean Association board of directors (NASDAQ:LPCN)
www.4-traders.com - August 16 at 6:08 PM
finance.yahoo.com logoSHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Lawsuit Involving Lipocine Inc. and a Lead Plaintiff Deadline of August 30, 2016 (NASDAQ:LPCN)
finance.yahoo.com - August 15 at 6:13 PM
finance.yahoo.com logoLundin Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 15 at 6:13 PM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Lipocine, Inc. (LPCN) and Lead Plaintiff Deadline - August 30, 2016 (NASDAQ:LPCN)
finance.yahoo.com - August 15 at 8:10 AM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Lipocine, Inc. (LPCN) & Lead Plaintiff Deadline: August 30, 2016 (NASDAQ:LPCN)
finance.yahoo.com - August 11 at 6:19 PM
finance.yahoo.com logoDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm (NASDAQ:LPCN)
finance.yahoo.com - August 11 at 6:19 PM
finance.yahoo.com logoLPCN: Working Through CRL; FDA Meeting Next Step (NASDAQ:LPCN)
finance.yahoo.com - August 11 at 6:19 PM

Social

Lipocine (NASDAQ:LPCN) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff